SetPoint Medical
received FDA approval in July 2025 for its neuroimmune modulation therapy for rheumatoid arthritis, the first clinically proven neuromodulation treatment for the condition, and its RESET-RA study was published in Nature Medicine in January 2026 demonstrating durable efficacy and safety;…
- Country
- United States
FDA approved
Neuroimmune modulation
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioelectronic medicine & neuromodulation | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.